Format

Send to

Choose Destination
Curr Opin Pharmacol. 2006 Aug;6(4):364-8. Epub 2006 Jun 5.

Inhibition of poly(ADP-ribose) polymerase in cancer.

Author information

1
Northern Institute for Cancer Research, Paul O'Gorman Building, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. e.r.plummer@ncl.ac.uk

Abstract

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.

PMID:
16753340
DOI:
10.1016/j.coph.2006.02.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center